Immix Biopharma (IMMX)
Nasdaq Market Closed
Immix Biopharma Inc is a clinical-stage biotechnology company developing therapies for cancer and other serious diseases. The company’s work is focused on novel cell therapies and drug candidates intended to address difficult-to-treat conditions, including hematologic malignancies and solid tumors. As a development-stage biopharma business, Immix does not operate like a commercial drug manufacturer; its prospects depend on clinical progress, regulatory review, financing and the potential medical value of its pipeline.
The company describes part of its approach as Tissue-Specific Therapeutics, with technology designed to alter or normalize the tumor microenvironment. The tumor microenvironment includes blood vessels, immune cells, signaling molecules and structural components surrounding a tumor. By targeting more than the cancer cell alone, Immix aims to improve how therapies reach diseased tissue and attack the broader system that supports tumor growth.
Immix’s pipeline includes NXC-201, a CAR-T cell therapy candidate being evaluated for serious immune-mediated and blood-related diseases, and IMX-110, a drug candidate being developed for soft tissue sarcoma and other oncology indications. CAR-T therapies use engineered immune cells to recognize and attack disease targets, a field that has become an important area of innovation in hematologic cancers but remains scientifically and commercially complex.
The company is listed on Nasdaq under the symbol IMMX. Its investment profile is typical of early clinical biotechnology stocks: potential upside is tied to trial data, partnerships and regulatory milestones, while risks include clinical failure, safety concerns, dilution from capital needs and long timelines before any possible product approval or revenue.
Last updated
- Market Cap
- 600.84M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 521.59M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 11400 WEST OLYMPIC BLVD., LOS ANGELES, CA, 90064
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 - GlobeNewswire
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Immix Biopharma 12 Month Review Progress Update
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
Immix Biopharma Announces Proposed Public Offering of Common Stock
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 600.84M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 521.59M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 7.12
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -14.57
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -0.49
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -32.77M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -41.41%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -36.46%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 8.76
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 8.76
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 7.52
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.14M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 8.44
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -10.8M | -10.89M | -7.66M | -6.72M | -4.68M |
| EBITDA | -10.71M | -10.84M | -7.57M | -6.68M | -4.64M |
| Net income | -10.04M | -10.69M | -7.59M | -6.62M | -4.53M |
| Basic EPS | -0.18 | -0.28 | -0.24 | -0.22 | -0.15 |
| Diluted EPS | -0.18 | -0.28 | -0.24 | -0.22 | -0.15 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 95.82M | 104.84M | 20.08M | 15.64M | 19.89M |
| Total liabilities | 11.45M | 11.04M | 11.82M | 10.98M | 10.3M |
| Total equity | 84.36M | 93.8M | 8.26M | 4.65M | 9.59M |
| Cash & equivalents | 79.25M | 93.93M | 15.95M | 11.64M | 15.92M |
| Current assets | 92.27M | 101.24M | 16.58M | 12.33M | 16.78M |
| Current liabilities | 10.54M | 10.11M | 10.85M | 10.01M | 9.31M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -9.83M | -11.03M | -5.91M | -5.31M | -1.69M |
| Investing cash flow | -4.8M | -6.65M | -372.46K | -127.63K | -67.71K |
| Financing cash flow | -37.56K | 95.67M | 10.61M | 1.11M | — |
| Change in cash | -14.68M | 77.98M | 4.31M | -4.28M | -1.76M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Hsu Jason | View Filing | |
| form 4 | Form 4 — Hsu Jason | View Filing | |
| form 4 | Form 4 — Hsu Jason | View Filing | |
| form 4 | Form 4 — Hsu Jason | View Filing | |
| form 4 | Form 4 — BUCHAN JANE | View Filing | |
| form 4 | Form 4 — BUCHAN JANE | View Filing | |
| form 4 | Form 4 — Chudnovsky Yekaterina | View Filing | |
| form 4 | Form 4 — Chudnovsky Yekaterina | View Filing | |
| form 4 | Form 4 — Chudnovsky Yekaterina | View Filing | |
| form 4 | Form 4 — Rachman Ilya M | View Filing | |
| form 4 | Form 4 — CHANG NANCY T | View Filing | |
| form 4 | Form 4 — CHANG NANCY T | View Filing | |
| form 4 | Form 4 — CHANG NANCY T | View Filing | |
| form 4 | Form 4 — Marquet Magda | View Filing | |
| form 4 | Form 4 — Marquet Magda | View Filing | |
| form 4 | Form 4 — Marquet Magda | View Filing | |
| form 4 | Form 4 — Morris Gabriel S | View Filing | |
| form 4 | Form 4 — Adams Helen C. | View Filing | |
| form 4 | Form 4 — Adams Helen C. | View Filing | |
| form 4 | Form 4 — Ng Carey | View Filing | |
| form 4 | Form 4 — Ng Carey | View Filing | |
| form 4 | Form 4 — Ng Carey | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| edgar index | FWP — Immix Biopharma, Inc. | View Filing | |
| edgar index | 424B5 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Immix Biopharma, Inc. | View Filing | |
| edgar index | 10-Q — Immix Biopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Immix Biopharma, Inc. | View Filing | |
| edgar index | DEF 14A — Immix Biopharma, Inc. | View Filing | |
| edgar index | DEFA14A — Immix Biopharma, Inc. | View Filing | |
| edgar index | ARS — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K/A — Immix Biopharma, Inc. | View Filing | |
| edgar index | 10-K — Immix Biopharma, Inc. | View Filing | |
| edgar index | 424B5 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| edgar index | S-8 — Immix Biopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G — Immix Biopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Immix Biopharma, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Immix Biopharma, Inc. | View Filing | |
| edgar index | EFFECT — Immix Biopharma, Inc. | View Filing | |
| edgar index | UPLOAD — Immix Biopharma, Inc. | View Filing | |
| edgar index | CORRESP — Immix Biopharma, Inc. | View Filing | |
| edgar index | S-3 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 4 — Immix Biopharma, Inc. | View Filing | |
| form 4 | Form 4 — Morris Gabriel S | View Filing | |
| form 4 | Form 4 — Rachman Ilya M | View Filing | |
| edgar index | FWP — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| edgar index | 424B5 — Immix Biopharma, Inc. | View Filing | |
| edgar index | 8-K — Immix Biopharma, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Morris Gabriel S | View Filing |